Hikma Buys Teligent Assets To Expand Into Canada
Deal Worth $46m For Canadian Sterile Injectable Assets Follows Teligent Bankruptcy
Executive Summary
Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.
You may also be interested in...
Hikma Hikes Generics Guidance As It Prepares For New CEO
After a tough 2022 for its generics business, Hikma is predicting big things for the division this year, raising its full-year guidance from 20% growth to nearly 30% as new CEO Riad Mishlawi prepares to take the reins from the start of September. Meanwhile, the firm has also picked up assets from Akorn following its collapse.
Hikma Marks Milestone With US Injectables Launches
Hikma has passed a milestone with its US injectables portfolio after the latest trio of launches.
Juno Looks To Shore Up Canada Supply Chains With Omega Deal
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.